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INTRODUCTION AND OBJECTIVE
Recently an extensive effort has been made in the development of smart, 
functional, organized delivery system by layer-by-layer (LBL) self-assembling 
technique for micro/nano-encapsulation of bioactives, Caruso [2001]; Decher and 
Schlenoff [2003]. The encapsulation of bioactive materials into porous 
microparticles of inorganic origin have a great potential to allocate the drug in 
their nanopores (nanoreservoir) and have features to impart biological stability 
along with sustained release properties. We have made an attempt to develop a 
novel formulation of paclitaxel (PTX) by providing multilayer assembly over 
drug loaded porous CaCO3 microparticles (CaCO3 MP) by using combination of 
biocompatible and biodegradable polyelectrolytes (PE’ s). There has been a 
paradigm shift in the delivery of PTX and research being focused to eliminate 
intrinsic problem associated with drug itself and toxicity associated with 
excipients used in the existing formulation. 
XRD comparison chart between PTX, CaCO3-PTX, and CaCO3   
MP. 
CHARACTERIZATION
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This alternative delivery system of PTX disguised in the form of LBL assembly 
could have been immense application for the treatment of metastasized mammary 
glands vis-à-vis existing formulation of PTX which is by and large criticized for 
having certain toxic excipients to be given parentrally. Further investigations are 
still underway to gather toxicity profile of the proposed formulation. 
A B
A: SEM of porous CaCO3 MP
B: SEM of fabricated CaCO3-PTX (PRM/SA)5
    Scale bar 1 mμ  
IN-VITRO RELEASE  PROFILE
•  Nanoporous structure of inorganic decomposable core (charge substrate, 
CaCO3) has been used for encapsulation of PTX and fabricated by LBL 
assembly of polyelectrolyte (PE’ s) using electrostatic 
interaction due to its great importance in geo-, bio-, and material sciences, 
as well as due to its wide industrial, technological  and drug delivery 
applications.
•  Shape, surface morphology and narrow size distribution ranging from 4-6 µm of 
the CaCO3  microparticles and fabricated capsules were presented by the 
particle size analyzer and SEM photomicrographs. 
•  Zeta potential study reveals layer-by-layer growth of the systems.
•  The release profile of PTX-(PRM/SA)5  indicates that PEs based multilayer 
matrix is capable to provide barrier to PTX release as it has been found to follow 
first order matrix diffusion kinetics (r2= 0.9973) with 72±4.8% release within 
24 hrs. The t50% of PTX-M, CaCO3-PTX and PTX- (PRM/SA)5 was found to be 70, 
90 and 480 minutes respectively. 
SEM OF POROUS CaCO3 MP AND FABRICATED 
CAPSULES
IR spectra of A. CaCO3 MP B. PTX and C. CaCO3-PTX. 
Mean particle size & size distribution of CaCO3 MP (Average 
(d.nm):3558) and CaCO3-PTX (PRM/SA)5 (Average 
(d.nm):4110) 
A
B
TGA curve of A. PTX; B. CaCO3-PTX, and C. CaCO3  MP. 
TGA curve of A. CaCO3-PTX (PRM/SA)5, and 
B. PTX (PRM/SA)5 
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Drug release profile of formulations in SIF (pH=7.4): F-
1:CaCO3-PTX; F-2: PTX (PRM/SA)5 and F-3: PTX-M. 
CHARACTERIZATION
CaCO3-PTX MP Fabricated capsules
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spectroscopy
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TGA
Drug release profile   in 
SIF (pH=7.4)
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